Clinical trials: Metastatic Cancers
Melanoma
STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma
This study is designed to assess the efficacy of a weekly treatment regimen of STA-4783 and paclitaxel in comparison to paclitaxel alone on tumor response in metastatic melanoma patients.
- Trial name
- NCT00084214
- Testing
- STA-4783, Paclitaxel
- Where
- 28 sites in United States
- Volunteers
- 103 people
- Sponsor
- Synta Pharmaceuticals Corp.
Advanced or Metastatic MTAP-deleted Solid Tumors
An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors
This study is being done to learn more about a new drug called BG-89894 (previously known as SYH2039). Researchers want to see if the drug is safe, how well people can tolerate it, how it moves through the body, and whether it…
- Trial name
- NCT06568614
- Testing
- BG-89894
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 29 people
- Sponsor
- BeOne Medicines
Pancreatic Cancer
A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
Purpose of this phase I/II study is to test how well LY2090314 works in combination with different chemotherapies in treating participants with metastatic pancreatic cancer.
- Trial name
- NCT01632306
- Testing
- LY2090314, FOLFOX, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Eli Lilly and Company
Ewing Sarcoma, Ewing Family of Tumors
A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
The goal of this clinical trial was to compare participants with first relapse or refractory Ewing's sarcoma when treated with investigational product (Vigil) in addition to the standard treatment of irinotecan and temozolomide…
- Conditions
- Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic
- Trial name
- VITA (NCT03495921)
- Testing
- Vigil, Irinotecan, Temozolomide
- Where
- 15 sites in United States
- Volunteers
- 32 people
- Sponsor
- Gradalis, Inc.
Advanced Cancer, Gastric Cancer
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
This is an open label Phase I/IIa, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody as monotherapy or in combination with nivolumab or standard of care.
- Conditions
- Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
- Trial name
- NCT04396821
- Testing
- TST001, Nivolumab Injection [Opdivo], mFOLFOX6
- Where
- 18 sites in United States
- Volunteers
- 150 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Advanced or Inoperable Gastric Cancer
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
This study enrolled participants with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms.
- Trial name
- NCT03427814
- Testing
- Pamiparib
- Where
- 65 sites in United States, Australia and 14 more
- Volunteers
- 136 people
- Sponsor
- BeiGene
Malignant Solid Tumor
A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours
This is a two part Phase I/Ib, open-label, non-randomized and multi-center, dose escalation study with a 3+3 design (Part 1) and an expansion cohort at the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) (Part 2).
- Trial name
- NCT03009214
- Testing
- AMC303
- Where
- 7 sites in Belgium, Spain
- Volunteers
- 55 people
- Sponsor
- amcure GmbH
Metastatic Colorectal Cancer
Patients' Guidance With Onco-Coaching and CANKADO on Systemic Chemotherapy for Metastatic Colorectal Cancer
This is a prospective, single arm, non-interventional project to evaluate the benefit/influence of individualized patient education and guidance with a web-based e-Health platform called CANKADO on patient reported outcomes (PRO)…
- Trial name
- POSCA (NCT04393116)
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Cankado GmbH
Esophageal Cancer
Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer
The Phase Ib stage of this study primarily aims to evaluate the tolerance and safety of TQB6411 Injection in participants with recurrent or metastatic Esophageal cancer who have previously failed treatment with PD-1/PD-L1…
- Trial name
- NCT07367516
- Testing
- TQB6411 Injection
- Where
- 30 sites in China
- Volunteers
- 105 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Urothelial Carcinoma
A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 combination therapy in patients with locally advanced or metastatic urothelial carcinoma.
- Trial name
- NCT06405425
- Testing
- BL-B01D1, PD-1
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Melanoma
Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma.
- Trial name
- NCT04091217
- Testing
- Atezolizumab, Bevacizumab
- Where
- 3 sites in China
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Bone Metastatic Non-small Cell Lung Cancer
A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis
AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met, suggesting that its anti-tumor effect mainly inhibits the activation of key downstream oncogenic pathways by inhibiting expression of…
- Trial name
- NCT04325776
- Testing
- AL2846, Zoledronic Acid Injection
- Where
- 8 sites in China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Lung Cancer, Non-Small Cell
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
The goal of this clinical trial is to evaluate the safety and tolerability profile of dostarlimab in combination with belrestotug when compared with pembrolizumab and placebo in participants with previously untreated…
- Trial name
- NCT06472076
- Testing
- Dostarlimab, Belrestotug, Pembrolizumab
- Where
- 108 sites in United States, Argentina and 19 more
- Volunteers
- 88 people
- Sponsor
- GlaxoSmithKline
Malignant Pleural Mesothelioma
Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma
The main objective of the trial is to document the progression free survival (PFS) in advanced or metastatic malignant pleural mesothelioma patients treated with NGR-hTNF as single agent.
- Trial name
- NGR010 (NCT00484276)
- Testing
- NGR-hTNF
- Where
- 4 sites in Italy
- Volunteers
- 57 people
- Sponsor
- AGC Biologics S.p.A.
Nasopharyngeal Neoplasms
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the safety and efficacy of CC-486 in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma having failed one to two previous regimens, including…
- Trial name
- NCT02269943
- Testing
- CC-486
- Where
- 25 sites in United States, Canada and 7 more
- Volunteers
- 36 people
- Sponsor
- Celgene
Solid Tumors
MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors
The main purpose of this study was to assess the safety and tolerability of MSB0011359C. Study consists of dose-escalation part and an expansion part in participants with metastatic or locally advanced solid tumors, for which no…
- Trial name
- NCT02699515
- Testing
- MSB0011359C
- Where
- 18 sites in Japan, South Korea and 1 more
- Volunteers
- 114 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer
The study is intended to investigate the safety of BYL719 and AUY922 in patients with advanced gastric cancer, and to determine the MTD and/or RDE of both drugs in combination.
- Trial name
- NCT01613950
- Testing
- AUY922, BYL719
- Where
- 9 sites in United States, Germany and 4 more
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid…
- Conditions
- Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT07503808
- Testing
- IDE034
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- IDEAYA Biosciences
Non Small Cell Lung Cancer
A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer
The purpose of this study is to test the safety and determine the optimal dose of a new drug, demcizumab (OMP-21M18), when given in combination with carboplatin and pemetrexed, a standard drug treatment regimen for non-squamous…
- Trial name
- NCT01189968
- Testing
- Demcizumab
- Where
- 7 sites in Australia, New Zealand and 1 more
- Volunteers
- 50 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Head and Neck Neoplasms
Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The objective of this study is to evaluate in a 3 +3 design, the safety of escalating doses of Monalizumab given IV in combination with cetuximab in patients who have received prior systemic regimen(s) for recurrent and/or…
- Trial name
- NCT02643550
- Testing
- Monalizumab, Cetuximab, Anti-PD(L)1
- Where
- 18 sites in United States, France
- Volunteers
- 143 people
- Sponsor
- Innate Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.